These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38596311)

  • 1. Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.
    McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM; Ryan S; Raphael S; van Faassen H; Zafer A; Zhu Q; Maclean S; Chattopadhyay A; Gurnani K; Gilbert R; Gadoury C; Iqbal U; Fatehi D; Jezierski A; Huang J; Pon RA; Sigrist M; Holt RA; Nelson BH; Atkins H; Kekre N; Yung E; Webb J; Nielsen JS; Weeratna RD
    Mol Ther Oncol; 2024 Mar; 32(1):200775. PubMed ID: 38596311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy.
    Abbaszade Dibavar M; Soleimani M; Mohammadi MH; Zomorrod MS
    In Vitro Cell Dev Biol Anim; 2024 Apr; 60(4):321-332. PubMed ID: 38589736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
    Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
    Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
    J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia.
    Zhang T; Wang T; You F; Li Z; Chen D; Zhang K; Tian S; Sheng B; Wu H; Jiang L; Ma R; An G; Meng H; Yang L
    Transpl Immunol; 2022 Apr; 71():101538. PubMed ID: 35051588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.
    Qin H; Ramakrishna S; Nguyen S; Fountaine TJ; Ponduri A; Stetler-Stevenson M; Yuan CM; Haso W; Shern JF; Shah NN; Fry TJ
    Mol Ther Oncolytics; 2018 Dec; 11():127-137. PubMed ID: 30581986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
    Zanetti SR; Velasco-Hernandez T; Gutierrez-Agüera F; Díaz VM; Romecín PA; Roca-Ho H; Sánchez-Martínez D; Tirado N; Baroni ML; Petazzi P; Torres-Ruiz R; Molina O; Bataller A; Fuster JL; Ballerini P; Juan M; Jeremias I; Bueno C; Menéndez P
    Mol Ther; 2022 Feb; 30(2):550-563. PubMed ID: 34478871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
    Zhang Y; Li S; Wang Y; Lu Y; Xu Y; Rao Q; Wang H; Xing H; Tian Z; Tang K; Lv L; Wang M; Wang J
    Exp Hematol Oncol; 2022 Mar; 11(1):15. PubMed ID: 35317863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanobody-based CAR-T cells for cancer immunotherapy.
    Safarzadeh Kozani P; Naseri A; Mirarefin SMJ; Salem F; Nikbakht M; Evazi Bakhshi S; Safarzadeh Kozani P
    Biomark Res; 2022 Apr; 10(1):24. PubMed ID: 35468841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
    Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.
    Nguyen TT; Thanh Nhu N; Chen CL; Lin CF
    Cancer Med; 2023 Sep; 12(18):18767-18785. PubMed ID: 37667978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.
    Ereño-Orbea J; Liu X; Sicard T; Kucharska I; Li W; Borovsky D; Cui H; Feng Y; Dimitrov DS; Julien JP
    J Biol Chem; 2021 Aug; 297(2):100966. PubMed ID: 34273351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
    Haso W; Lee DW; Shah NN; Stetler-Stevenson M; Yuan CM; Pastan IH; Dimitrov DS; Morgan RA; FitzGerald DJ; Barrett DM; Wayne AS; Mackall CL; Orentas RJ
    Blood; 2013 Feb; 121(7):1165-74. PubMed ID: 23243285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.
    Ramakrishna S; Highfill SL; Walsh Z; Nguyen SM; Lei H; Shern JF; Qin H; Kraft IL; Stetler-Stevenson M; Yuan CM; Hwang JD; Feng Y; Zhu Z; Dimitrov D; Shah NN; Fry TJ
    Clin Cancer Res; 2019 Sep; 25(17):5329-5341. PubMed ID: 31110075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
    Schneider D; Xiong Y; Wu D; Hu P; Alabanza L; Steimle B; Mahmud H; Anthony-Gonda K; Krueger W; Zhu Z; Dimitrov DS; Orentas RJ; Dropulić B
    Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.